» Articles » PMID: 35935336

Effects of 3-methylmethcathinone on Conditioned Place Preference and Anxiety-like Behavior: Comparison with Methamphetamine

Overview
Specialty Molecular Biology
Date 2022 Aug 8
PMID 35935336
Authors
Affiliations
Soon will be listed here.
Abstract

3-Methylmethcathinone (3-MMC), a drug belonging to synthetic cathinones family, raised public attention due to its harmful health effects and abuse potential. Although it has similar properties to other cathinone derivatives, the behavioral effects of 3-MMC remain largely unknown. In the present research, we evaluated the rewarding effect of 3-MMC using conditioned place preference (CPP) paradigm and its effect on anxiety-like behavior using elevated plus maze (EPM) and compared with methamphetamine (METH). Then, we performed a whole-brain c-Fos mapping to identify the specific brain regions in response to 3-MMC exposure and explored the changes of synaptic transmission in nucleus accumbens (NAc) using patch-clamp recording after chronic 3-MMC and METH exposure. 3-MMC induced CPP at higher doses of 3 or 10 mg/kg in rats and acute exposure of 3 mg/kg 3-MMC to rats produced anxiolytic-like effect, while anxiety-like behavior was increased after 7 days of injection with 3-MMC. Whole-brain immunostaining revealed increased c-Fos expression in anterior cingulate cortex (ACC), NAc and ventral tegmental area (VTA) after chronic 3-MMC injection compared with saline, which was similar to METH. Especially, 3-MMC induced more neural activation of VTA compared with METH. Finally, we found that amplitude of spontaneous inhibitory postsynaptic currents (sIPSCs) in NAc was decreased after chronic 3-MMC injection, while frequency of sIPSCs and spontaneous excitatory postsynaptic currents (sEPSCs) were not affected. Taken together, our results revealed the addictive potential of 3-MMC and its effect on anxiety-like behavior, which warn the risks of 3-MMC abuse and justify the control of synthetic cathinones. And 3-MMC selectively inhibit inhibitory but not excitatory transmission onto neurons in NAc, which may contribute to its effects.

Citing Articles

Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study.

Ramaekers J, Reckweg J, Mason N, Kuypers K, Toennes S, Theunissen E Neuropsychopharmacology. 2024; .

PMID: 39719487 DOI: 10.1038/s41386-024-02042-7.


Metaphedrone (3-Methylmethcathinone): Pharmacological, Clinical, and Toxicological Profile.

Kelecevic I, Vejnovic A, Javorac J, Gvozdenovic N, Janjic N, Mijatovic Jovin V Medicina (Kaunas). 2024; 60(3).

PMID: 38541192 PMC: 10972361. DOI: 10.3390/medicina60030466.


3'-Deoxyadenosin alleviates methamphetamine-induced aberrant synaptic plasticity and seeking behavior by inhibiting the NLRP3 inflammasome.

Qi Y, Zhou Y, Li J, Zhu F, Guo G, Wang C Neural Regen Res. 2024; 19(10):2270-2280.

PMID: 38488561 PMC: 11034599. DOI: 10.4103/1673-5374.392887.


Quantifying conditioned place preference: a review of current analyses and a proposal for a novel approach.

Yates J Front Behav Neurosci. 2023; 17:1256764.

PMID: 37693282 PMC: 10484009. DOI: 10.3389/fnbeh.2023.1256764.


An orbitofrontal cortex-anterior insular cortex circuit gates compulsive cocaine use.

Chen Y, Wang G, Zhang W, Han Y, Zhang L, Xu H Sci Adv. 2022; 8(51):eabq5745.

PMID: 36563158 PMC: 9788779. DOI: 10.1126/sciadv.abq5745.

References
1.
Liu Z, Lin R, Luo M . Reward Contributions to Serotonergic Functions. Annu Rev Neurosci. 2020; 43:141-162. DOI: 10.1146/annurev-neuro-093019-112252. View

2.
Frison G, Frasson S, Zancanaro F, Tedeschi G, Zamengo L . Detection of 3-methylmethcathinone and its metabolites 3-methylephedrine and 3-methylnorephedrine in pubic hair samples by liquid chromatography-high resolution/high accuracy Orbitrap mass spectrometry. Forensic Sci Int. 2016; 265:131-7. DOI: 10.1016/j.forsciint.2016.01.039. View

3.
Waterhouse B, Navarra R . The locus coeruleus-norepinephrine system and sensory signal processing: A historical review and current perspectives. Brain Res. 2018; 1709:1-15. DOI: 10.1016/j.brainres.2018.08.032. View

4.
Shima N, Katagi M, Kamata H, Zaitsu K, Kamata T, Nishikawa M . Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), in humans and rats. Xenobiotica. 2008; 38(3):314-24. DOI: 10.1080/00498250701802506. View

5.
Nair A, Jacob S . A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016; 7(2):27-31. PMC: 4804402. DOI: 10.4103/0976-0105.177703. View